Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DEFENSE HEALTH AGENCY (DHA)

Contract Value

Not provided

Codes & Classification
Solicitation Number

HT9402-26-Q-9404

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

NONE

Place of Performance

San Antonio, Texas, UNITED STATES

SourceSAM
The Department of War, through the Defense Health Agency (DHA), has issued a solicitation (HT9402-26-Q-9404) for the establishment of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP). This procurement is mandated by 10 U.S.C. § 1074g and its implementing regulation (32 CFR Section 199.21), which require the creation of an integrated, efficient pharmacy benefits program for the Military Health System (MHS). The program’s primary objective is to ensure the effective acquisition and management of pharmaceutical agents for military beneficiaries, guided by clinical and cost-effectiveness considerations. The scope of this solicitation encompasses the purchase and formulary placement of pharmaceutical agents within specific drug classes, as determined by the DoW Pharmacy and Therapeutics (P&T) Committee. The committee evaluates the clinical and cost effectiveness of drugs in each therapeutic class, recommending their inclusion in the Uniform Formulary (UF) and their classification for cost-sharing purposes (generic, formulary, Basic Core Formulary [BCF], Extended Core Formulary [ECF], or non-formulary [NF]). The current solicitation is issued in advance of the November 2026 P&T Committee meeting, during which newly approved drugs in various subclasses will be reviewed. These include topical agents, white blood cell stimulants, oncological agents, antiretrovirals, antifungals, breast cancer agents, insulins, immunomodulatory biologics, hematological agents, antibiotics, RAS inhibitors, and alcohol deterrents. Key requirements for contractors include the submission of quotations for pharmaceutical agents identified for potential UF placement. The RFQ, along with UF BPA and UF ADP appendices, provides detailed instructions, deadlines, and points of contact. Notably, a pre-quotation teleconference is scheduled for October 14, 2026, with specifics outlined in Part 2.4 of the RFQ. Contractors are required to respond to clinical questions (Part 3.4) via email to the designated point of contact by the deadline specified in Part 2.3.2. The procurement is classified under NAICS Code 325412 (Pharmaceutical Preparation Manufacturing), with Product Service Code 6505. There are no set-aside requirements, making this opportunity open to all qualified entities. The place of performance is San Antonio, Texas, and the contracting entity is the Defense Health Agency, a federal office under the Department of Defense. For further information, contractors may contact Tracy Banks ([email protected]) or Kirk Heyen ([email protected]). The solicitation remains active, with a response deadline of October 26, 2026, at 17:10. Interested parties are encouraged to review the attached RFQ and associated documents for comprehensive instructions and requirements. This opportunity is particularly relevant for manufacturers and suppliers of pharmaceutical preparations who can meet the clinical and cost-effectiveness standards set by the DHA and are prepared to engage in the UF BPA and UF ADP programs. The contract’s core elements—formulary management, clinical review, and cost-sharing classification—will remain central throughout its lifecycle, ensuring ongoing alignment with the MHS’s pharmacy benefit objectives. For full details and access to solicitation documents, visit the official notice at https://sam.gov/opp/1b4dc95103b348fe8d1f0aed614fc920/view.
Documents16